


This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1. (currently amended): Substituted pyrazoline compounds of ~~general~~ formula I,



wherein

R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, SO₂R⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched C₁₋₆ alkyl,

R⁵ and R⁶ independently of each other represent a linear or branched C₁₋₆ alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ ~~and~~ or -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C₁₋₆ alkyl;

R⁷ represents hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂,

NHR^{10} , $\text{NR}^{10}\text{R}^{11}$, $-(\text{C}=\text{O})-\text{NH}_2$, $-(\text{C}=\text{O})\text{NHR}^{10}$ ~~and or~~ $-(\text{C}=\text{O})-\text{NR}^{10}\text{R}^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;


with the proviso that

if R^1 and R^7 are H and R^5 and R^6 both represent Cl in the 3- and 4-position of the phenyl ring neither of R^2 , R^3 and R^4 may represent F in the 4-position of the phenyl ring if the other two of R^2 , R^3 and R^4 both represent H;

optionally in a form of one of ~~the~~ its stereoisomers, ~~preferably enantiomers or diastereomers, or a~~ racemate or in a form of a mixture of at least two of ~~the~~ its stereoisomers, ~~preferably enantiomers and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

2. (original): Compounds according to claim 1, characterized in that at least one of R^2 , R^3 or R^4 represents hydrogen, while at least one of R^2 , R^3 or R^4 is different from hydrogen.
3. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~or 2~~, characterized in that R^7 represents hydrogen.
4. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~to 3~~, characterized in that R^2 , R^3 and R^4 independently of each other represent hydrogen, a linear or branched C_{1-6} -alkyl group, a halogen atom, or CF_3 , ~~preferably R^2 , R^3 and R^4 independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF_3 .~~
5. (currently amended): Compounds according to ~~any one of claims~~ claim 1 ~~to 4~~, characterized in that R^5 and R^6 independently of each other represent a linear or branched C_{1-6} -alkyl group, a halogen atom, or CF_3 , ~~preferably R^5 and R^6 independently of each other represent methyl, ethyl, F, Cl, Br and CF_3 .~~

6. (currently amended): Compounds according to ~~any one of claims~~ claim 1 to 5, characterized in that R^2 represents a chlorine atom in the 4-position of the phenyl ring, while R^3 and R^4 represent hydrogen.
7. (currently amended): Compounds according to ~~any one of claims~~ claim 1 to 6, characterized in that R^5 and R^6 each represent a chlorine atoms in the 2- and 4-position of the phenyl ring, while R^7 represents hydrogen.
8. (currently amended): Compounds according to ~~any one of claims~~ claim 1 to 7, characterized in that R^1 represents hydrogen, methyl or ethyl, ~~preferably hydrogen~~.
9. (currently amended): Compounds of ~~general~~ formula II according to ~~any one of claims~~ claim 1 to 8



wherein

R^1 represents hydrogen or a linear or branched C_{1-4} -alkyl group,

R¹² or R¹³ independently of each other represent a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, hydrogen, methyl, ethyl, F, Cl, Br ~~and~~ or CF₃,

R¹⁴ or R¹⁵ independently of each other represent a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, SH, NH₂, methyl, ethyl, F, Cl, Br ~~and~~ or CF₃,

optionally in a form of one of ~~the~~ its stereoisomers, ~~preferably enantiomers or diastereomers, or a~~
racemate or in a form of a mixture of at least two of ~~the~~ its stereoisomers, ~~preferably enantiomers~~
~~and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a
physiologically acceptable salt thereof, or a corresponding solvate thereof.


10. (currently amended): Compounds according to claim 9 characterized in that R¹² and R¹³ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃, ~~preferably R¹² and R¹³ independently of each other represent hydrogen, methyl, ethyl, F, Cl, Br and CF₃.~~
11. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~or 10~~, characterized in that R¹⁴ and R¹⁵ independently of each other represent a linear or branched C₁₋₆-alkyl group, a halogen atom, or CF₃, ~~preferably R¹⁴ and R¹⁵ independently of each other represent methyl, ethyl, F, Cl, Br and CF₃.~~
12. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~to 11~~, characterized in that R¹³ represents Cl and R¹² represents hydrogen.
13. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~to 12~~, characterized in that R¹⁴ and R¹⁵ each represent Cl.
14. (currently amended): Compounds according to ~~any one of claims~~ claim 9 ~~to 13~~, characterized in that R¹ represents hydrogen, methyl or ethyl, ~~preferably hydrogen.~~

15. (currently amended): ~~A compound~~ Compounds according to one or more of claims claim 1 to 14
~~selected from the group consisting of which is:~~

5-(4-chloro-phenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxylic acid,

optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.

16. (currently amended): Combination of compounds comprising at least one substituted pyrazoline compound of ~~general~~ formula I



wherein


R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, SO₂R⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched C₁₋₆-alkyl,

R^5 , R^6 and R^7 independently of each other represent hydrogen, a linear or branched C_{1-6} -alkyl group, a linear or branched C_{1-6} -alkoxy group, a halogen atom, CH_2F , CHF_2 , CF_3 , CN , OH , NO_2 , $-(C=O)-R^{10}$, SH , SR^{10} , SOR^{10} , NH_2 , NHR^{10} , $NR^{10}R^{11}$, $-(C=O)-NH_2$, $-(C=O)-NHR^{10}$ ~~and or~~ $-(C=O)-NR^{10}R^{11}$, whereby R^{10} and optionally R^{11} for each substituent independently represent linear or branched C_{1-6} alkyl;

optionally in a form of one of ~~the its~~ stereoisomers, ~~preferably enantiomers or diastereomers, or a~~ racemate or in a form of a mixture of at least two of ~~the its~~ stereoisomers, ~~preferably enantiomers and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

and at least one substituted pyrazoline compound of general formula X



X

wherein

R^{16} represents an optionally at least mono-substituted phenyl group,

R^{17} represents an optionally at least mono-substituted phenyl group,

R^{18} represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an $-NR^{19}R^{20}$ -moiety,

R^{19} and R^{20} , identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system ~~and/or~~ or bonded via a linear or branched alkylene group, an -SO₂- R^{21} -moiety, or an -NR²² R^{23} -moiety, with the proviso that R^{19} and R^{20} do not identically represent hydrogen,


R^{21} represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system ~~and/or~~ or bonded via a linear or branched alkylene group,

R^{22} and R^{23} , identical or different, represent a hydrogen atom, an unbranched or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic radical, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system ~~and/or~~ or bonded via a linear or branched alkylene group,

optionally in a form of one of ~~the~~ its stereoisomers, ~~preferably enantiomers or diastereomers, or a~~ racemate or in a form of a mixture of at least two of ~~the~~ its stereoisomers, ~~preferably enantiomers and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.


Claims 17-39 (canceled)

40. (currently amended): Process for the manufacture of substituted pyrazoline compounds of ~~general~~ formula I or II, wherein R^1 is hydrogen, according to ~~one or more of claims~~ claim 1 to 15, characterized in that at least one benzaldehyde compound of ~~general~~ formula III




(III)

wherein R^2 , R^3 and R^4 have the meaning according to ~~one or more of claims 1-8~~ claim 1, is reacted with a pyruvate compound of ~~general~~ formula (IV)




(IV),

wherein G represents an OR group with R being a branched or unbranched C_{1-6} alkyl radical or G represents an O^-K group with K being a cation, to yield a compound of ~~general~~ formula (V)




(V)

which is optionally isolated ~~and/or~~ or optionally purified, and which is reacted with an optionally substituted phenyl hydrazine of ~~general~~ formula (VI)



(VI)

or a corresponding salt thereof, wherein R⁵, R⁶ and R⁷ have the meaning according to ~~one or~~ ~~more of claims 1-8~~ claim 1, under inert atmosphere, to yield a compound of ~~general~~ formula (VII)




(VII)

wherein R², R³, R⁴, R⁵, R⁶ and R⁷ have the meaning as given above, which is optionally isolated ~~and/or~~ or optionally purified, and optionally esterified to an alkyl-ester if in the substituted pyrazoline compound of ~~general~~ formula I according to ~~one or more of claims~~ claim 1 ~~to 15~~ R¹ is a linear or branched C₁₋₄-alkyl group.

41. (currently amended): Medicament comprising at least one substituted pyrazoline compound of ~~general~~ formula I or II according to ~~one or more of claims~~ claim 1 ~~to 15~~, and optionally one or more pharmaceutically acceptable excipients.

42. (currently amended): Medicament comprising at least one substituted pyrazoline compound of general formula I



wherein

R¹ represents hydrogen or a linear or branched C₁₋₄-alkyl group,

R², R³ and R⁴ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R⁸, SH, SR⁸, SOR⁸, SO₂R⁸, NH₂, NHR⁸, NR⁸R⁹, -(C=O)-NH₂, -(C=O)-NHR⁸ or -(C=O)-NR⁸R⁹ whereby R⁸ and R⁹ for each substituent independently represent linear or branched C₁₋₆ alkyl,

R⁵, R⁶ and R⁷ independently of each other represent hydrogen, a linear or branched C₁₋₆-alkyl group, a linear or branched C₁₋₆-alkoxy group, a halogen atom, CH₂F, CHF₂, CF₃, CN, OH, NO₂, -(C=O)-R¹⁰, SH, SR¹⁰, SOR¹⁰, NH₂, NHR¹⁰, NR¹⁰R¹¹, -(C=O)-NH₂, -(C=O)-NHR¹⁰ ~~and or~~ -(C=O)-NR¹⁰R¹¹, whereby R¹⁰ and optionally R¹¹ for each substituent independently represent linear or branched C₁₋₆ alkyl;

optionally in a form of one of ~~the its~~ stereoisomers, ~~preferably enantiomers or diastereomers,~~ or a racemate or in a form of a mixture of at least two of ~~the its~~ stereoisomers, ~~preferably enantiomers~~

~~and/or diastereomers,~~ in any mixing ratio, or a corresponding N-oxide thereof, or a physiologically acceptable salt thereof, or a corresponding solvate thereof;

and optionally one or more pharmaceutically acceptable excipients.

Claims 43-64 (canceled)

65. (currently amended): A method ~~Use of at least one substituted pyrazoline compound according to one or more of claims 1-15 or at least one combination of compounds according to one or more of claims 16 to 39 and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the regulation of triglyceride levels in the blood plasma~~ and for the prophylaxis ~~and/or~~ or ~~treatment of disorders of disorders of the central nervous system, especially stroke, of disorders of the cardiovascular system and~~ or ~~of food intake disorders, especially bulimia, anorexia, cachexia, obesity, type II diabetes mellitus (non-insuline dependent diabetes mellitus), preferably obesity and diabetis,~~ the method comprising administering one or more substituted pyrazoline compounds of claim 1 and optionally one or more pharmaceutically acceptable excipients.

Claims 66-86 (canceled)